Matches in SemOpenAlex for { <https://semopenalex.org/work/W2508758352> ?p ?o ?g. }
- W2508758352 abstract "Bevacizumab, a humanized monoclonal antibody (mAb) targeting to the vascular endothelial growth factor (VEGF), has been widely used in clinical practice for the treatment of multiple cancers. Bevacizumab was mostly produced by the mammalian cell expression system. We here reported the first plant-derived Bevacizumab by using transgenic rice callus as an alternative gene expression system. Codon-optimized Bevacizumab light chain (BLC) and Bevacizumab heavy chain (BHC) genes were designed, synthesized as a polyprotein with a 2A self-cleavage linker peptide from the Foot-and-mouth disease virus, cloned into a plant binary vector under a constitutive maize ubiquitin promoter, and transformed into rice nuclear genome through Agrobacterium-mediated transformation. Southern blot and western blot analyses confirmed the integration and expression of BLC and BHC genes in transgenic rice callus. Enzyme-linked immunosorbent assay (ELISA) analysis indicated that the rice-derived Bevacizumab mAb was biologically active and the recombinant mAb was expressed at high levels (160.7-242.8 mg/Kg) in transgenic rice callus. The mAb was purified by using protein A affinity chromatography and the purified antibody was tested for its binding affinity with its target human VEGF (hVEGF) antigen by ELISA. Rice callus produced Bevacizumab and a commercial Bevacizumab (Avastin) were shown to have similar binding affinity to hVEGF. These results indicated that rice callus produced Bevacizumab could have similar biological activity and might potentially be used as a cost-effective biosimilar molecule in future cancer treatment." @default.
- W2508758352 created "2016-09-16" @default.
- W2508758352 creator A5010738468 @default.
- W2508758352 creator A5050725077 @default.
- W2508758352 creator A5055279606 @default.
- W2508758352 creator A5072783081 @default.
- W2508758352 date "2016-08-09" @default.
- W2508758352 modified "2023-10-17" @default.
- W2508758352 title "Efficient Production of a Bioactive Bevacizumab Monoclonal Antibody Using the 2A Self-cleavage Peptide in Transgenic Rice Callus" @default.
- W2508758352 cites W1532698890 @default.
- W2508758352 cites W1560712586 @default.
- W2508758352 cites W1678784904 @default.
- W2508758352 cites W1823508533 @default.
- W2508758352 cites W1893730694 @default.
- W2508758352 cites W1908675203 @default.
- W2508758352 cites W1950388476 @default.
- W2508758352 cites W1970363110 @default.
- W2508758352 cites W1973060237 @default.
- W2508758352 cites W1976202571 @default.
- W2508758352 cites W1979971043 @default.
- W2508758352 cites W1984333418 @default.
- W2508758352 cites W1984374025 @default.
- W2508758352 cites W1992961087 @default.
- W2508758352 cites W1993617984 @default.
- W2508758352 cites W1995562003 @default.
- W2508758352 cites W1997561434 @default.
- W2508758352 cites W1997607253 @default.
- W2508758352 cites W1997719377 @default.
- W2508758352 cites W1999676950 @default.
- W2508758352 cites W2002803179 @default.
- W2508758352 cites W2004538569 @default.
- W2508758352 cites W2005343613 @default.
- W2508758352 cites W2005979110 @default.
- W2508758352 cites W2007553857 @default.
- W2508758352 cites W2008539212 @default.
- W2508758352 cites W2011326234 @default.
- W2508758352 cites W2012063336 @default.
- W2508758352 cites W2014637687 @default.
- W2508758352 cites W2015027812 @default.
- W2508758352 cites W2016604591 @default.
- W2508758352 cites W2018412706 @default.
- W2508758352 cites W2018604605 @default.
- W2508758352 cites W2019990270 @default.
- W2508758352 cites W2022225492 @default.
- W2508758352 cites W2022254881 @default.
- W2508758352 cites W2025738827 @default.
- W2508758352 cites W2027147867 @default.
- W2508758352 cites W2033382475 @default.
- W2508758352 cites W2034911101 @default.
- W2508758352 cites W2047694403 @default.
- W2508758352 cites W2049343886 @default.
- W2508758352 cites W2050405684 @default.
- W2508758352 cites W2053194563 @default.
- W2508758352 cites W2053677609 @default.
- W2508758352 cites W2053948371 @default.
- W2508758352 cites W2057275076 @default.
- W2508758352 cites W2058438178 @default.
- W2508758352 cites W2060037459 @default.
- W2508758352 cites W2067067694 @default.
- W2508758352 cites W2071202867 @default.
- W2508758352 cites W2071919990 @default.
- W2508758352 cites W2072408667 @default.
- W2508758352 cites W2075892193 @default.
- W2508758352 cites W2078624174 @default.
- W2508758352 cites W2080205209 @default.
- W2508758352 cites W2080576612 @default.
- W2508758352 cites W2081633887 @default.
- W2508758352 cites W2093084676 @default.
- W2508758352 cites W2097546894 @default.
- W2508758352 cites W2097641133 @default.
- W2508758352 cites W2100756525 @default.
- W2508758352 cites W2102375023 @default.
- W2508758352 cites W2104036642 @default.
- W2508758352 cites W2108874048 @default.
- W2508758352 cites W2111306551 @default.
- W2508758352 cites W2123760882 @default.
- W2508758352 cites W2124111803 @default.
- W2508758352 cites W2127992607 @default.
- W2508758352 cites W2129331774 @default.
- W2508758352 cites W2130008544 @default.
- W2508758352 cites W2130052699 @default.
- W2508758352 cites W2130286786 @default.
- W2508758352 cites W2133612043 @default.
- W2508758352 cites W2142765731 @default.
- W2508758352 cites W2154200023 @default.
- W2508758352 cites W2155119422 @default.
- W2508758352 cites W2157171008 @default.
- W2508758352 cites W2157212209 @default.
- W2508758352 cites W2159015766 @default.
- W2508758352 cites W2166836758 @default.
- W2508758352 cites W2168252233 @default.
- W2508758352 cites W2175291039 @default.
- W2508758352 cites W2206841326 @default.
- W2508758352 cites W2282326788 @default.
- W2508758352 cites W2327880790 @default.
- W2508758352 cites W2332792005 @default.
- W2508758352 cites W2524178063 @default.
- W2508758352 cites W2580449060 @default.
- W2508758352 cites W58751442 @default.
- W2508758352 doi "https://doi.org/10.3389/fpls.2016.01156" @default.